New generation Alzheimer’s diagnostics

Aß 1-42, Aß 1-40 and T-tau ELISAs

New generation Alzheimer’s diagnostics

A new generation of ELISAs provides standardized, automated analysis of beta-amyloid (Aß) peptides (Aß 1-42 and Aß 1-40) and total tau (T-tau) proteins in cerebrospinal fl uid (CSF), facilitating diagnosis...

Supplied by EUROIMMUN AG


A new generation of ELISAs provides standardized, automated analysis of beta-amyloid (Aß) peptides (Aß 1-42 and Aß 1-40) and total tau (T-tau) proteins in cerebrospinal fl uid (CSF), facilitating diagnosis of Alzheimer’s disease in its early stages. The concentrations of these biomarkers reflect the Alzheimer’s-specific neuropathological changes in the brain. A significant decrease in Aß 1-42 is observed as many as 5 to 10 years before the start of cognitive changes. Aß 1-40 remains unchanged. The determination of the ratio Aß 1-42 to Aß 1-40 increases the efficiency of early diagnostics and might help to discriminate Alzheimer’s disease from vascular dementia. The concentrations of T-tau and phosphorylated tau (P-tau) increase when patients develop advanced neurodegeneration and cognitive impairment. Th e Aß 1-42, Aß 1-40 and T-tau ELISAs have been developed by Euroimmun in collaboration with ADx Neurosciences. They are based on a sandwich principle employing well-characterized capture antibodies. This matrix-independent methodology ensures extremely high consistency in results. The assays are CE-certified and include lyophilized calibrators for added convenience and precision. The procedures are highly standardized and can be automated on Euroimmun analysers and other open ELISA platforms.


Contact form

Get in touch directly with the above supplier

Your email address will not be communicated to any third party other than the above supplier for the purpose of fulfilling this enquiry. For more information: read our privacy policy.